PAIM
AUPH icon

Punch & Associates Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Punch & Associates Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-300
Closed -$741 – 176
2015
Q4 		$741 Buy
+300
New +$815 ﹤0.01% 271

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Punch & Associates Investment Management's AUPH Position: Q1 2016 in Review

Punch & Associates Investment Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2016, closing a stake of 300 shares — an estimated $741 sold.

Punch & Associates Investment Management first reported a position in AUPH in Q4 2015 and held it in 1 quarter. The position peaked at $741 in Q4 2015. 17 funds tracked by Wall St. Rank hold AUPH as of Q1 2016.

  • Punch & Associates Investment Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Punch & Associates Investment Management sold 300 Aurinia Pharmaceuticals shares in Q1 2016, an estimated $741.
  • Punch & Associates Investment Management first reported a position in Aurinia Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Punch & Associates Investment Management's Aurinia Pharmaceuticals position peaked at $741 in Q4 2015.
  • 17 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2016.

Based on Punch & Associates Investment Management's 13F filing for Q1 2016, filed 25 Apr 2016.